31st European Society of Gene and Cell Therapy Congress
In the realm of therapeutic innovation, cell therapy clinical trials are not just progressing; they're revolutionizing the landscape of patient care with the potential for life-altering treatments. Syneos Health stands at the epicenter of this transformation.
In Europe, where the promise of lifelong disease management is becoming a tangible reality, we acknowledge and address the unique challenges that stand in the path of this medical evolution. We are proactively tackling the intricate issues of manufacturing capacity, navigating the complexities of cost structures, and unraveling the elaborate tapestry of market access.
Through our Cell and Gene Therapy Development Engine, Syneos Health is committed to surmounting these hurdles, ensuring that groundbreaking therapies are not only conceived but also successfully delivered to those in need.
Meet with Us
Meet with us at the ESGCT Congress to discuss how our collective knowledge and insights can be fully leveraged to deliver solutions specific to the needs of your trial—and make each study as safe and effective for patients as possible.
Our Attendees
Abhi Gupta, Senior Vice President & Head of Cell and Gene Therapy, Syneos Health
Abhi Gupta joined Syneos Health in April 2023 as Senior Vice President, Head of Cell and Gene Therapy. In his role, he drives the development and operationalization of strategic clinical and commercial solutions that accelerate the impact of life-changing genetic medicines for Syneos Health customers and their patients. Prior to Syneos Health, Abhi held various leadership and scientific positions at Pfizer, Regeneron, Citigroup, BMS, and Johnson & Johnson. He is passionate about improving the real-world life experiences of genetic medicine patients and their families and overcoming the pressing challenges of cell and gene therapy research.
Jane K. Bentley, PhD, Vice President, Therapeutic Strategy & Innovation, Oncology and Hematology, Syneos Health
Jane is a distinguished professional in the pharmaceutical industry with over 35 years of experience in oncology drug development. Since May 2016, Jane has been with Syneos Health, where she is passionate about driving strategic innovation in oncology. Her work involves collaborating closely with clients and internal teams to develop and implement solutions-based approaches to drug development, ensuring that new therapies are developed efficiently and effectively. Jane's leadership extends to spearheading cross-functional innovation initiatives, focusing on the patient voice, cell and gene therapy, and rare disease, underlining her dedication to incorporating patient perspectives and addressing the challenges of complex treatments.
Contenu apparenté
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
A Holistic Approach to Genetic Medicines is Next for the Life Science Industry
Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies
Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients
Strategies for Small Biotech in the Development of Cell Therapy Trials
View more of our insights on Cell & Gene Therapy.
Learn more about our Cell & Gene Therapy expertise.
